Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
3billion | RCV003153042 | SCV003841763 | pathogenic | Alagille syndrome due to a JAG1 point mutation | 2023-02-23 | criteria provided, single submitter | clinical testing | The variant is not observed in the gnomAD v2.1.1 dataset. This variant was predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported to be associated with JAG1 related disorder (PMID: 16575836). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. |
Prevention |
RCV004741463 | SCV005363292 | pathogenic | JAG1-related disorder | 2024-08-15 | no assertion criteria provided | clinical testing | The JAG1 c.1713delC variant is predicted to result in a frameshift and premature protein termination (p.Cys572Valfs*3). This variant has been reported as causative for Alagille syndrome (Warthen et al. 2006. PubMed ID: 16575836; Gilbert et al. 2019. PubMed ID: 31343788). This variant has not been reported in a large population database, indicating this variant is rare. Frameshift variants in JAG1 are expected to be pathogenic. This variant is interpreted as pathogenic. |